Lyra Therapeutics Inc. sued NACS Inc., claiming the contract manufacturer wasted more than $10 million of the pharmaceutical company’s money by ignoring quality control and producing “zero usable product.”
The lawsuit, made public Thursday, accuses NACS of breaching its agreements with Lyra, which included warranties and other protections covering any defects in the drug-device combination NACS was manufacturing, an “innovative” treatment for chronic nasal sinus inflammation.
NACS repeatedly “allowed product that was too long, too short, the incorrect weight, or, incredibly, was contaminated with insects, cardboard, and glass, to pass through its ‘inspection’ procedures,” according to the complaint.
The problems ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.